Actively Recruiting

Age: 18Years - 80Years
All Genders
NCT06585761

Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

Led by Kafrelsheikh University · Updated on 2024-09-05

60

Participants Needed

1

Research Sites

71 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this study is to explore the effect of SGLT2i on the levels of cardiac biomarkers, inflammatory and stress markers in Egyptian heart failure patients to provide a better understanding of mechanism that might assist in tailoring treatment strategies in patients with various forms of HF especially in Egyptian population. Also understand how biomarkers may be employed to predict risk in patients receiving SGLT2i or identification of those who may derive the most benefit from SGLT2i in the means of individualized medicine.

CONDITIONS

Official Title

Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged more than 18 years old
  • Heart failure patients with cardiac function classified as NYHA class II-IV
  • Patients receiving standard heart failure therapy according to guidelines, including ACE inhibitors, ARBs, ARNI, beta blockers, mineralocorticoid receptor antagonists, and diuretics as needed
  • All patients must have signed informed consent
Not Eligible

You will not qualify if you...

  • Patients with acute cardiovascular illness or severe sepsis that could affect inflammatory markers
  • Patients with severe congenital heart disease, myocarditis, or valvular heart disease
  • Female patients who are pregnant or breastfeeding
  • Patients with malignant tumors, hyperfunctioning thyroid, multiple organ failure, or severely reduced kidney function (eGFR <20 mL/min/1.73 m²)
  • Patients with verbal communication disorders or cognitive impairment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Kafrelsheikh University Hospital

Kafr ash Shaykh, Egypt, 33516

Actively Recruiting

Loading map...

Research Team

N

Nada Nabil mohammed elsalhey, BSC

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here